Aclarion (NASDAQ:ACON) & InnovAge (NASDAQ:INNV) Head-To-Head Review

Aclarion (NASDAQ:ACON) and InnovAge (NASDAQ:INNV) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, dividends, earnings, valuation and risk.

Institutional & Insider Ownership

7.5% of Aclarion shares are owned by institutional investors. Comparatively, 12.3% of InnovAge shares are owned by institutional investors. 0.8% of Aclarion shares are owned by insiders. Comparatively, 1.0% of InnovAge shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Aclarion has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Comparatively, InnovAge has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500.

Valuation and Earnings

This table compares Aclarion and InnovAge”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$50,000.00	46.75	-$6.99 million	($15.00)	-0.18
InnovAge	$853.70 million	1.33	-$30.31 million	$0.05	167.20

Aclarion has higher earnings, but lower revenue than InnovAge. Aclarion is trading at a lower price-to-earnings ratio than InnovAge, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Aclarion and InnovAge, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1	0	0	0	1.00
InnovAge	1	1	0	1	2.33

InnovAge has a consensus price target of $5.00, indicating a potential downside of 40.19%. Given InnovAge’s stronger consensus rating and higher possible upside, analysts plainly believe InnovAge is more favorable than Aclarion.

Profitability

This table compares Aclarion and InnovAge’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,908.50%	-67.53%	-63.01%
InnovAge	0.71%	2.60%	1.23%

Summary

InnovAge beats Aclarion on 11 of the 14 factors compared between the two stocks.

About Aclarion

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

About InnovAge

InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in its homes and communities. The company manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. It also offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the PACE center and third-party medical appointments; and care management. The company serves participants in the United States; and operates PACE centers in Colorado, California, New Mexico, Pennsylvania, Florida, and Virginia. The company was formerly known as TCO Group Holdings, Inc. and changed its name to InnovAge Holding Corp. in January 2021. InnovAge Holding Corp. was founded in 2007 and is headquartered in Denver, Colorado.